nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.0332	0.0499	CcSEcCtD
Ezogabine—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.0296	0.0445	CcSEcCtD
Ezogabine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.0249	0.0373	CcSEcCtD
Ezogabine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.0211	0.0317	CcSEcCtD
Ezogabine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.0205	0.0308	CcSEcCtD
Ezogabine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0306	CcSEcCtD
Ezogabine—Coma—Riluzole—amyotrophic lateral sclerosis	0.0183	0.0274	CcSEcCtD
Ezogabine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.0172	0.0258	CcSEcCtD
Ezogabine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0232	CcSEcCtD
Ezogabine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0232	CcSEcCtD
Ezogabine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.0145	0.0218	CcSEcCtD
Ezogabine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0145	0.0218	CcSEcCtD
Ezogabine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0142	0.0213	CcSEcCtD
Ezogabine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0138	0.0207	CcSEcCtD
Ezogabine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0201	CcSEcCtD
Ezogabine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0188	CcSEcCtD
Ezogabine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.0125	0.0188	CcSEcCtD
Ezogabine—KCNQ5—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.0123	0.0502	CbGpPWpGaD
Ezogabine—KCNQ4—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.0123	0.0502	CbGpPWpGaD
Ezogabine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0176	CcSEcCtD
Ezogabine—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0176	CcSEcCtD
Ezogabine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0171	CcSEcCtD
Ezogabine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0168	CcSEcCtD
Ezogabine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0168	CcSEcCtD
Ezogabine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.0107	0.016	CcSEcCtD
Ezogabine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0159	CcSEcCtD
Ezogabine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00999	0.015	CcSEcCtD
Ezogabine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00992	0.0149	CcSEcCtD
Ezogabine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00989	0.0148	CcSEcCtD
Ezogabine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00985	0.0148	CcSEcCtD
Ezogabine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00939	0.0141	CcSEcCtD
Ezogabine—KCNQ2—brainstem—amyotrophic lateral sclerosis	0.00935	0.106	CbGeAlD
Ezogabine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00888	0.0133	CcSEcCtD
Ezogabine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0088	0.0132	CcSEcCtD
Ezogabine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00874	0.0131	CcSEcCtD
Ezogabine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00841	0.0126	CcSEcCtD
Ezogabine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00819	0.0123	CcSEcCtD
Ezogabine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00811	0.0122	CcSEcCtD
Ezogabine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00788	0.0118	CcSEcCtD
Ezogabine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00786	0.0118	CcSEcCtD
Ezogabine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00784	0.0118	CcSEcCtD
Ezogabine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00783	0.0117	CcSEcCtD
Ezogabine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00768	0.0115	CcSEcCtD
Ezogabine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00742	0.0111	CcSEcCtD
Ezogabine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00735	0.011	CcSEcCtD
Ezogabine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00728	0.0109	CcSEcCtD
Ezogabine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.0072	0.0108	CcSEcCtD
Ezogabine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00709	0.0106	CcSEcCtD
Ezogabine—KCNQ3—medulla oblongata—amyotrophic lateral sclerosis	0.00709	0.0807	CbGeAlD
Ezogabine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00702	0.0105	CcSEcCtD
Ezogabine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.007	0.0105	CcSEcCtD
Ezogabine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00699	0.0105	CcSEcCtD
Ezogabine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.0069	0.0104	CcSEcCtD
Ezogabine—KCNQ2—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.00667	0.0271	CbGpPWpGaD
Ezogabine—KCNQ3—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.00667	0.0271	CbGpPWpGaD
Ezogabine—KCNQ5—nervous system—amyotrophic lateral sclerosis	0.00663	0.0755	CbGeAlD
Ezogabine—KCNQ4—cerebellum—amyotrophic lateral sclerosis	0.00642	0.0731	CbGeAlD
Ezogabine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00641	0.00962	CcSEcCtD
Ezogabine—KCNQ5—central nervous system—amyotrophic lateral sclerosis	0.00639	0.0727	CbGeAlD
Ezogabine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00955	CcSEcCtD
Ezogabine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00634	0.00952	CcSEcCtD
Ezogabine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00628	0.00943	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00616	0.00925	CcSEcCtD
Ezogabine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00615	0.00923	CcSEcCtD
Ezogabine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00916	CcSEcCtD
Ezogabine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00588	0.00883	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00539	0.0219	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00539	0.0219	CbGpPWpGaD
Ezogabine—KCNQ3—nervous system—amyotrophic lateral sclerosis	0.00532	0.0606	CbGeAlD
Ezogabine—KCNQ4—brain—amyotrophic lateral sclerosis	0.00521	0.0594	CbGeAlD
Ezogabine—KCNQ3—central nervous system—amyotrophic lateral sclerosis	0.00513	0.0584	CbGeAlD
Ezogabine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00512	0.00768	CcSEcCtD
Ezogabine—KCNQ5—brain—amyotrophic lateral sclerosis	0.00507	0.0577	CbGeAlD
Ezogabine—KCNQ3—cerebellum—amyotrophic lateral sclerosis	0.00501	0.0571	CbGeAlD
Ezogabine—KCNQ5—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00497	0.0202	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00497	0.0202	CbGpPWpGaD
Ezogabine—KCNQ2—nervous system—amyotrophic lateral sclerosis	0.0049	0.0558	CbGeAlD
Ezogabine—KCNQ4—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.0048	0.0195	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.0048	0.0195	CbGpPWpGaD
Ezogabine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00708	CcSEcCtD
Ezogabine—KCNQ2—central nervous system—amyotrophic lateral sclerosis	0.00472	0.0537	CbGeAlD
Ezogabine—KCNQ2—cerebellum—amyotrophic lateral sclerosis	0.00461	0.0525	CbGeAlD
Ezogabine—Rash—Riluzole—amyotrophic lateral sclerosis	0.0045	0.00675	CcSEcCtD
Ezogabine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0045	0.00675	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00439	0.0179	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00439	0.0179	CbGpPWpGaD
Ezogabine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00636	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00415	0.0169	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00408	0.0166	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00408	0.0166	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00408	0.0166	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00408	0.0166	CbGpPWpGaD
Ezogabine—KCNQ3—brain—amyotrophic lateral sclerosis	0.00407	0.0463	CbGeAlD
Ezogabine—KCNQ2—brain—amyotrophic lateral sclerosis	0.00375	0.0426	CbGeAlD
Ezogabine—KCNQ5—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00364	0.0148	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00364	0.0148	CbGpPWpGaD
Ezogabine—NAT2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00317	0.0129	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00291	0.0118	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00291	0.0118	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00291	0.0118	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00269	0.0109	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00269	0.0109	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00259	0.0105	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00259	0.0105	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00251	0.0102	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00242	0.00982	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00237	0.00965	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00237	0.00965	CbGpPWpGaD
Ezogabine—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.00229	0.0261	CbGeAlD
Ezogabine—KCNQ2—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.00223	0.00906	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.00223	0.00906	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00221	0.00897	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00221	0.00897	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00221	0.00897	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00221	0.00897	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00213	0.00865	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00209	0.0085	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00197	0.00799	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00197	0.00799	CbGpPWpGaD
Ezogabine—UGT1A4—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.00192	0.00782	CbGpPWpGaD
Ezogabine—CYP2A6—brain—amyotrophic lateral sclerosis	0.00186	0.0212	CbGeAlD
Ezogabine—NAT2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00186	0.00755	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00183	0.00745	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00177	0.00719	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—amyotrophic lateral sclerosis	0.00172	0.00701	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00167	0.00679	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00167	0.00679	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00164	0.00667	CbGpPWpGaD
Ezogabine—UGT1A3—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.0016	0.0065	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.00159	0.00647	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.00159	0.00647	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00144	0.00587	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00144	0.00587	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00142	0.00579	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00142	0.00579	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00136	0.00554	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.00136	0.00553	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.0013	0.00529	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00129	0.00523	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00128	0.00522	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00122	0.00497	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00122	0.00497	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00121	0.00492	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00114	0.00463	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00112	0.00457	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00111	0.00452	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00111	0.00451	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.0011	0.00449	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.0011	0.00449	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00107	0.00434	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—DAO—amyotrophic lateral sclerosis	0.00103	0.00418	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00102	0.00413	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000945	0.00384	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000942	0.00383	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000942	0.00383	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000942	0.00383	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000935	0.0038	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000922	0.00375	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000889	0.00361	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000862	0.00351	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000862	0.00351	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000788	0.00321	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000779	0.00317	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000736	0.003	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000736	0.003	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000733	0.00298	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000726	0.00295	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000719	0.00293	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000716	0.00291	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000716	0.00291	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000689	0.0028	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000655	0.00266	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000646	0.00263	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000646	0.00263	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000637	0.00259	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000637	0.00259	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—DAO—amyotrophic lateral sclerosis	0.000623	0.00253	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000609	0.00248	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000609	0.00248	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000591	0.0024	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000575	0.00234	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000573	0.00233	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000568	0.00231	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000518	0.00211	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000498	0.00203	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000495	0.00201	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000495	0.00201	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000495	0.00201	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000495	0.00201	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000478	0.00194	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000478	0.00194	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000472	0.00192	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000462	0.00188	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000453	0.00184	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000453	0.00184	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSR—amyotrophic lateral sclerosis	0.000436	0.00177	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000429	0.00175	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000429	0.00175	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000421	0.00171	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000421	0.00171	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000396	0.00161	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000396	0.00161	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000393	0.0016	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000382	0.00155	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000382	0.00155	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSR—amyotrophic lateral sclerosis	0.000362	0.00147	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000358	0.00146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000358	0.00146	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000358	0.00146	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000349	0.00142	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000341	0.00139	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000341	0.00139	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000324	0.00132	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000317	0.00129	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	0.000306	0.00125	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	0.000306	0.00125	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000305	0.00124	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000297	0.00121	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000292	0.00119	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000276	0.00112	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000271	0.0011	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000271	0.0011	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSR—amyotrophic lateral sclerosis	0.00025	0.00102	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	0.00025	0.00102	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—APOE—amyotrophic lateral sclerosis	0.00024	0.000976	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000228	0.000927	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000209	0.00085	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000206	0.000836	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000206	0.000836	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	0.000193	0.000785	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000192	0.000782	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000188	0.000763	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000177	0.000719	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000164	0.000669	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.00016	0.00065	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000158	0.000644	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000147	0.000598	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—APOE—amyotrophic lateral sclerosis	0.000145	0.000591	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000129	0.000523	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—APOE—amyotrophic lateral sclerosis	0.000121	0.000492	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.00011	0.000449	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.00011	0.000449	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000102	0.000413	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000102	0.000413	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.96e-05	0.000405	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.52e-05	0.000346	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	8.35e-05	0.00034	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	8.35e-05	0.00034	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.28e-05	0.000337	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.83e-05	0.000318	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	6.44e-05	0.000262	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.72e-05	0.000233	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.72e-05	0.000233	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.41e-05	0.000179	CbGpPWpGaD
